Receptor conversion and survival in breast cancer liver metastases

Breast Cancer Research

Research

Robert Lundqvist¹  Anne Andersson²  Sofia Norgren³  Marcus Sundén³  Malin Sund⁴  Oskar Hemmingsson⁵ 

[1] Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden;Department of Radiation Sciences/Oncology, Umeå University, Umeå, Sweden;Department of Surgical and Perioperative Sciences/Surgery, Umeå University, 901 85, Umeå, Sweden;Department of Surgical and Perioperative Sciences/Surgery, Umeå University, 901 85, Umeå, Sweden;Department of Surgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland;Department of Surgical and Perioperative Sciences/Surgery, Umeå University, 901 85, Umeå, Sweden;Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden;

关键词: Breast cancer;    Liver metastases;    Estrogen receptor;    Progesterone receptor;    Human epidermal growth factor receptor 2;   

DOI  :  10.1186/s13058-023-01706-4

 received in 2023-05-17, accepted in 2023-09-07,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundBreast cancer liver metastases (BCLM) is a common cause of breast cancer-related death. The prognostic and predictive value of receptor expression and St Gallen classification is challenged by receptor status discordance in distant metastases. The aim of this study was to determine the rate of receptor conversion from breast cancer to BCLM and the impact on survival.MethodPatients registered with BCLM in two Swedish national cancer registers were recruited retrospectively. Data on receptor expression in primary breast cancer and BCLM were collected, as well as information about predictive factors for survival. The rate of receptor and subtype conversion was analyzed. A Cox regression model was used to investigate predictive factors for survival.ResultsA cohort of 132 patients with BCLM was identified. Estrogen receptor (ER), progesterone receptor (PgR) and HER2 converted in 17, 33 and 10%, respectively. PgR was lost in BCLM while 8/10 HER2 conversions went from negative to positive. The BC subtype was re-classified in 21% of the BCLM. Median survival after BCLM was 13 months and HER2 amplification was associated with improved survival (HR 0.28 CI 0.085–0.90). The highest predictive value (Harrell´s C-index) was obtained when including both BC and BCLM status.ConclusionsReceptor and subtype conversions are common in BCLM, and a liver biopsy is warranted to tailor BCLM treatment. HER2 amplification is associated with improved survival in a BCLM cohort.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

12862_2023_2158_Article_IEq31.gif

Fig. 1

Fig. 1

12888_2023_5172_Article_IEq53.gif